MA35941B1 - Préparation pharmaceutique contenant un dérivé de dihydrochinazoline à action antivirale - Google Patents

Préparation pharmaceutique contenant un dérivé de dihydrochinazoline à action antivirale

Info

Publication number
MA35941B1
MA35941B1 MA37360A MA37360A MA35941B1 MA 35941 B1 MA35941 B1 MA 35941B1 MA 37360 A MA37360 A MA 37360A MA 37360 A MA37360 A MA 37360A MA 35941 B1 MA35941 B1 MA 35941B1
Authority
MA
Morocco
Prior art keywords
dihydrochinazoline
derivative
pharmaceutical preparation
preparation containing
antiviral action
Prior art date
Application number
MA37360A
Other languages
English (en)
Inventor
Kerstin Paulus
Wilfried Schwab
Dominique Grunder
Hoogevest Peter Van
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47757622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35941(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of MA35941B1 publication Critical patent/MA35941B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des préparations pharmaceutiques, notamment conçues pour une administration par voie intraveineuse, qui contiennent de l'acide {8-fluoro-2-[4-(3-méthoxyphényl)pipérazin-1-yl]-3-[2-méthoxy-5-(trifluorométhyl)phényl]
MA37360A 2012-02-29 2014-09-17 Préparation pharmaceutique contenant un dérivé de dihydrochinazoline à action antivirale MA35941B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012101680A DE102012101680A1 (de) 2012-02-29 2012-02-29 Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
PCT/EP2013/054114 WO2013127970A1 (fr) 2012-02-29 2013-02-28 Préparation pharmaceutique contenant un dérivé de dihydrochinazoline à action antivirale

Publications (1)

Publication Number Publication Date
MA35941B1 true MA35941B1 (fr) 2014-12-01

Family

ID=47757622

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37360A MA35941B1 (fr) 2012-02-29 2014-09-17 Préparation pharmaceutique contenant un dérivé de dihydrochinazoline à action antivirale

Country Status (37)

Country Link
US (1) US10603384B2 (fr)
EP (3) EP4328218A3 (fr)
JP (1) JP6387486B2 (fr)
KR (1) KR102149561B1 (fr)
CN (2) CN104144678A (fr)
AU (1) AU2013224947B2 (fr)
BR (1) BR112014020946B1 (fr)
CA (1) CA2865203C (fr)
CL (1) CL2014002306A1 (fr)
CO (1) CO7061076A2 (fr)
CY (1) CY1121910T1 (fr)
DE (1) DE102012101680A1 (fr)
DK (2) DK2819648T3 (fr)
EA (1) EA026584B1 (fr)
ES (2) ES2972133T3 (fr)
FI (1) FI3556350T3 (fr)
HK (1) HK1205462A1 (fr)
HR (2) HRP20240197T1 (fr)
HU (2) HUE045949T2 (fr)
IL (1) IL234363B (fr)
IN (1) IN2014MN01892A (fr)
LT (2) LT3556350T (fr)
MA (1) MA35941B1 (fr)
ME (1) ME03448B (fr)
MX (1) MX369666B (fr)
MY (1) MY172310A (fr)
NZ (1) NZ628444A (fr)
PH (1) PH12014501937A1 (fr)
PL (2) PL2819648T3 (fr)
PT (2) PT2819648T (fr)
RS (2) RS59157B1 (fr)
SG (1) SG11201405294XA (fr)
SI (2) SI2819648T1 (fr)
TN (1) TN2014000345A1 (fr)
UA (1) UA111415C2 (fr)
WO (1) WO2013127970A1 (fr)
ZA (1) ZA201405949B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) * 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
AU2014283231B2 (en) * 2013-06-19 2017-12-07 Aicuris Anti-Infective Cures Gmbh Amorphous Letermovir and solid pharmaceutical formulations thereof for oral administration
SG11201810836PA (en) 2016-06-03 2018-12-28 Atreya Innovations Private Ltd A device for the detection and reliable capturing of the pulse characteristics
CN110678186A (zh) * 2017-03-06 2020-01-10 维纳拓尔斯制药公司 包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途
AR121438A1 (es) 2020-02-27 2022-06-08 Aic246 Gmbh & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio
UY39099A (es) 2020-02-27 2021-08-31 Aic246 Gmbh & Co Kg 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmacéuticas del mismo
CN114539085B (zh) * 2020-11-26 2023-10-20 山东诚创蓝海医药科技有限公司 一种脲基衍生物的制备
CN115403528A (zh) * 2021-05-27 2022-11-29 南京正大天晴制药有限公司 无定形3,4-二氢喹唑啉衍生物的制备方法
CN113880776B (zh) * 2021-11-16 2023-06-16 山东诚创蓝海医药科技有限公司 一种莱特莫韦中间体的制备方法
AR128035A1 (es) 2021-12-21 2024-03-20 Aic246 Ag & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de potasio
CN115322157B (zh) * 2022-06-02 2023-12-05 浙江车头制药股份有限公司 来特莫韦中间体化合物及其制备方法和应用
CN115677539B (zh) * 2022-11-01 2023-10-24 南京工业大学 一种温和条件下钴催化脲基导向芳烃的高选择性单烯基化的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1242699A (fr) * 1985-02-01 1988-10-04 Bristol-Myers Company Cefbuperazone et ses derives
FR2585705B1 (fr) * 1985-08-05 1989-01-13 Bristol Myers Co Sels de cephalosporine et compositions injectables
JP3552240B2 (ja) * 1993-02-23 2004-08-11 第一製薬株式会社 高濃度ｔｃｆ製剤
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
IT1304190B1 (it) * 1998-12-18 2001-03-08 Euphar Group Srl Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche
PT1163237E (pt) * 1999-03-17 2004-08-31 Astrazeneca Ab Derivados de amida
WO2001091751A1 (fr) 2000-05-30 2001-12-06 Novo Nordisk A/S Nouvelle composition pharmaceutique et son procede de preparation
DE10319612A1 (de) * 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
KR20060127413A (ko) * 2003-11-25 2006-12-12 카이론 코포레이션 항암제로서의 퀴나졸리논 화합물
EP1846410B1 (fr) 2005-02-10 2009-01-21 Bristol-Myers Squibb Company Dihydroquinazolinones utilisees comme modulateurs de la 5ht
DE102005027517A1 (de) * 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
US8743287B2 (en) * 2009-07-24 2014-06-03 Broadcom Corporation Method and system for mitigating motion trail artifacts and improving low contrast contours in temporal filtering based noise reduction

Also Published As

Publication number Publication date
EP2819648B1 (fr) 2019-05-29
FI3556350T3 (fi) 2024-02-14
ES2972133T3 (es) 2024-06-11
MX369666B (es) 2019-11-14
MY172310A (en) 2019-11-21
DK2819648T3 (da) 2019-08-26
CY1121910T1 (el) 2020-10-14
CL2014002306A1 (es) 2014-11-28
US10603384B2 (en) 2020-03-31
PT2819648T (pt) 2019-09-05
CN104144678A (zh) 2014-11-12
AU2013224947B2 (en) 2017-06-29
EP3556350B1 (fr) 2024-01-10
MX2014010364A (es) 2014-12-05
WO2013127970A1 (fr) 2013-09-06
LT3556350T (lt) 2024-02-26
EP2819648A1 (fr) 2015-01-07
DK3556350T3 (da) 2024-02-12
KR102149561B1 (ko) 2020-08-31
ME03448B (fr) 2020-01-20
NZ628444A (en) 2016-07-29
UA111415C2 (uk) 2016-04-25
CA2865203C (fr) 2019-11-05
DE102012101680A1 (de) 2013-08-29
JP2015508801A (ja) 2015-03-23
SI2819648T1 (sl) 2019-10-30
ES2741698T3 (es) 2020-02-12
CA2865203A1 (fr) 2013-09-06
BR112014020946B1 (pt) 2022-04-05
BR112014020946A2 (fr) 2017-06-20
IN2014MN01892A (fr) 2015-07-10
PL3556350T3 (pl) 2024-05-06
SG11201405294XA (en) 2014-11-27
RS59157B1 (sr) 2019-10-31
CO7061076A2 (es) 2014-09-19
AU2013224947A1 (en) 2014-09-18
TN2014000345A1 (en) 2015-12-21
IL234363B (en) 2020-04-30
RS65137B1 (sr) 2024-02-29
ZA201405949B (en) 2021-07-28
JP6387486B2 (ja) 2018-09-12
EA026584B1 (ru) 2017-04-28
PT3556350T (pt) 2024-02-15
SI3556350T1 (sl) 2024-03-29
EP4328218A2 (fr) 2024-02-28
PL2819648T3 (pl) 2019-10-31
PH12014501937A1 (en) 2014-11-24
HUE065553T2 (hu) 2024-06-28
EA201400963A1 (ru) 2015-02-27
HK1205462A1 (en) 2015-12-18
EP4328218A3 (fr) 2024-04-10
HRP20191369T1 (hr) 2019-11-01
CN110433166A (zh) 2019-11-12
EP3556350A1 (fr) 2019-10-23
KR20140130683A (ko) 2014-11-11
HRP20240197T1 (hr) 2024-04-26
HUE045949T2 (hu) 2020-01-28
US20150133461A1 (en) 2015-05-14
LT2819648T (lt) 2019-09-10

Similar Documents

Publication Publication Date Title
MA35941B1 (fr) Préparation pharmaceutique contenant un dérivé de dihydrochinazoline à action antivirale
MA34727B1 (fr) Imidazolylimidazoles condensés utilisés comme composés antiviraux
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MY166045A (en) Abeta antibody formulation
MA38323B1 (fr) Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale
TN2014000283A1 (fr) Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA33462B1 (fr) Formulation pharmaceutique
TN2014000301A1 (fr) Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA38865A1 (fr) Formulation comprenant un agent hypolipidémiant
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
EA201391018A1 (ru) Препараты иммуносупрессантов
EA201890532A1 (ru) Новые аннелированные бензамиды
MA39146A1 (fr) Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
MA39983B1 (fr) Dérivés de carboxamide
BR112015023878A2 (pt) composto, composição farmacêutica, e, uso de um composto
SI3079688T1 (en) Chromium derivative as dopamine D3 RECEPTOR-ANTAGONIST FOR USE IN THE TREATMENT OF DISEASE OF AVTISTIC SPECTRUM
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
BR112012016549A2 (pt) piperazinas como agentes antimalariais
MA35010B1 (fr) Inhibiteurs de la peptide déformylase
MA37879B1 (fr) Forme amorphe stabilisée d'agomélatine, procédé pour sa préparation et compositions pharmaceutiques la contenant
CA2874566A1 (fr) Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance
MX2015012575A (es) Novedosos derivados de acrilamida como agentes contra la malaria.
MA37741B1 (fr) Dérivés de benzimidazole-proline
TH169698A (th) 4-ไฮดรอกซี-2-เมธิล-5-(โพรพาน-2-อิลิดีน)ไซโคลเฮก-3-อีนคาร์บาลดีไฮด์ สำหรับการป้องกันและการรักษาของความผิดปกติหรือโรคทางการรับรู้, ทางการเสื่อมของประสาท หรือ ทางประสาท